Publications by authors named "Miles Dale"

Claim this Profile
C
Clinical Pharmacology Considerations for the "Off-the-Shelf" Allogeneic Cell Therapies.
Hardik Mody, Dhruvitkumar S Sutaria, Dale Miles

Clin Pharmacol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R Flowers, Laurie H Sehn, Dale Miles

CPT Pharmacometrics Syst Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with -altered solid tumors.
Erick Velasquez, Nastya Kassir, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Dale Miles

Front Artif Intell· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Michael Z Liao, Dan Lu, Tong Lu, Leonid Gibiansky, Rong Deng, Dale Miles

Adv Drug Deliv Rev· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
Sharon P Shriver, Devon Adams, Brittany Avin McKelvey, Jeannine S McCune, Dale Miles

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Digital twins elucidate critical role of T in clinical persistence of TCR-engineered cell therapy".
Louis R Joslyn, Weize Huang, Dale Miles, Iraj Hosseini, Saroja Ramanujan

NPJ Syst Biol Appl· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Michael Z Liao, Rong Deng, Leonid Gibiansky, Tong Lu, Priya Agarwal, Dale Miles

Clin Transl Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
Hardik Mody, Ken Ogasawara, Xu Zhu, Dale Miles, Prathap Nagaraja Shastri

Clin Pharmacol Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling.
Stephanie N Liu, Priya Agarwal, Katja Heinig, Asim Datye, Carolina Sturm-Pellanda, Dale Miles

Clin Transl Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.
Dhruvitkumar S Sutaria, Priya Agarwal, Kuan-Chieh Huang, Dale R Miles, Jacob Rotmensch

Clin Transl Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology.
Weize Huang, Junyi Li, Michael Z Liao, Stephanie N Liu, Jiajie Yu, Dale R Miles

Clin Pharmacol Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.
Dhruvitkumar S Sutaria, Grozdana Rasuo, Adam Harris, Ryan Johnson, Dale Miles

Pharmaceutics· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Divya Samineni, Leonid Gibiansky, Bei Wang, Shweta Vadhavkar, Richa Rajwanshi, Dale Miles

Adv Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Review of Trauma ICU Patients With and Without Palliative Care Intervention.
Erica Rotundo, Elizabeth Braunreuther, Miles Dale, Aparna Vancheswaran, Joon Sub Lee

J Am Coll Surg· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, Dale Miles

Hematol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Divya Samineni, Weize Huang, Leonid Gibiansky, Hao Ding, Rong Zhang, Dale Miles

Adv Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Othman Al-Sawaf, Can Zhang, Tong Lu, Michael Z Liao, Anesh Panchal, Dale Miles

J Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Michael Z Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of medial arterial calcification on CBCT images of a patient with undiagnosed type 2 diabetes mellitus: a case report.
Adeyinka F Dayo, Dale A Miles, Beth R Hamann

Gen Dent· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients.
Miles Dale, Hiroshi Sogawa, Seyed Mohammad Seyedsaadat, David C Wolf, Roxana Bodin

Transplant Proc· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Sumit Bhatnagar, Dwaipayan Mukherjee, Ahmed Hamed Salem, Dale Miles, Rajeev M Menon

Cancer Chemother Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Sathej Gopalakrishnan, William Wierda, Brenda Chyla, Rajeev Menon, Dale Miles

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Dan Lu, Tong Lu, Rong Shi, Leonid Gibiansky, Priya Agarwal, Dale Miles

Pharm Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Divya Samineni, Hao Ding, Fang Ma, Rong Shi, Dan Lu, Dale Miles

J Clin Pharmacol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Rong Shi, Tong Lu, Grace Ku, Hao Ding, Tomohisa Saito, Dale Miles

Cancer Chemother Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis